Posts in tag

ImaginAb

Technology

LOS ANGELES and SAN DIEGO, Jan. 28, 2021 /PRNewswire/ — ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement. www.imaginab.com Under the terms of the agreement, ImaginAb will work with NEUVOGEN to …